Nabriva Therapeutics plc Gains 33.91%
Fri, May 29, 2020 at 05:30 PM
Nabriva Therapeutics plc (NBRV:NASDAQ) shot up at $1.14, representing a gain of 33.9%. On Thu 28 May 20, NBRV:NASDAQ hit a New 2-Week High of $0.85. The stock appeared on our News Catalysts scanner on Fri 29 May 20 at 08:35 AM in the 'BIOTECH' category. From Thu 14 May 20, the stock recorded 88.89% Up Days and 60.00% Green Days
About Nabriva Therapeutics plc (NBRV:NASDAQ)
Nabriva Therapeutics AG is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics.
Top 10 Gainers:
- Adaptimmune Therapeutics plc (ADAP:NASDAQ), 127.78%
- Sonoma Pharmaceuticals, Inc. (SNOA:NASDAQ), 79.3%
- AgeX Therapeutics, Inc. (AGE:NYSEMKT), 49.67%
- Pacific Ethanol, Inc. (PEIX:NASDAQ), 36.82%
- Phio Pharmaceuticals Corp. (PHIO:NASDAQ), 36.16%
- Millendo Therapeutics, Inc. (MLND:NASDAQ), 34.34%
- Nabriva Therapeutics plc (NBRV:NASDAQ), 33.91%
- Allied Esports Entertainment Inc. (AESE:NASDAQ), 33.88%
- Digital Ally, Inc. (DGLY:NASDAQ), 33.35%
- Agenus Inc. (AGEN:NASDAQ), 29.51%